Publication | Closed Access

Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors

MedicineMechanism Of ActionPharmacotherapyMet InhibitionDrug DevelopmentIi Met InhibitorsPharmacologyMet-dependent NsclcInhibitory ActivityDrug DiscoveryDrug Resistance